BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
    • BioWorld
    • BioWorld MedTech
    • Infographics: Dynamic digital data analysis
    • Index insights
    • NME Digest
  • Special reports
    • Infographics: Dynamic digital data analysis
    • Trump administration impacts
    • Under threat: mRNA vaccine research
    • BioWorld at 35
    • Biopharma M&A scorecard
    • Bioworld 2025 review
    • BioWorld MedTech 2025 review
    • BioWorld Science 2025 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Coronavirus
    • More reports can be found here

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe
BioWorld - Sunday, February 1, 2026
Home » Blogs » BioWorld MedTech Perspectives » MIS2013 coverage in 140 characters or less!

BioWorld MedTech Perspectives
BioWorld MedTech Perspectives RSS FeedRSS

Medical technology

MIS2013 coverage in 140 characters or less!

Oct. 21, 2013
By Amanda Pedersen

Love it or hate it, social media has become ingrained in most of our lives both personally and professionally. LinkedIn has made it easier than ever for professionals across business sectors to connect with one another and forge potential working relationships. And for those of us in the news business—especially those of us covering the ever volatile healthcare industry —the rise of Twitter has both enabled and demanded the delivery of real-time news in 140 characters or less.

The influence that social media, Twitter in particular, has on our professional lives was blatantly apparent in Cleveland last week where nearly 1,600 industry stakeholders gathered for the Cleveland Clinic’s 11th annual Medical Innovation Summit. This year’s meeting also served as the inaugural event at the Global Center for Health Innovation in Cleveland’s downtown.

This year, conference organizers went out of their way to encourage participants to “join the conversation” by displaying a scrolling Twitter feed on the screens behind the panel speakers. They also ran a friendly competition for Tweeting the best picture from the Tuesday night reception, which Medical Device Daily’s Executive Director Don Johnston proudly won, taking home an iPad Mini for his efforts. MDD also ranked fourth on a list of Top 10 Twitter mentions (the top three on that list

Cleveland's iconic Terminal Tower and the city's brand new Global Center for Health Innovation.
Cleveland's iconic Terminal Tower and the city's brand new Global Center for Health Innovation.

were all affiliated with the Cleveland Clinic and involved with the organization of the event).

Of course not everyone is a fan of social media. In fact, one over-served attendee at the networking reception Tuesday night was quick to express—using no uncertain terms—his dislike for the prominent display of Tweets running throughout the sessions. While it might have been seen as a distraction to some, the fact remains that Twitter, much like LinkedIn, has a legitimate place in the business world.

And in case you missed the conversation last week, here are some highlights from MDD’s Twitter coverage of the Medical Innovation Summit:

  • “We’re thinking of the post-EMR era of healthcare” – IBM Global Healthcare’s Sean Hogan on health IT panel.
  • Covidien CEO Almeida, native of Brazil, says obesity has become global challenge & “not just a developed country issue anymore.”
  • Transparency about cost is new for all in healthcare, representing significant challenge in changing environment. – Dr. [Toby] Cosgrove.
  • Obesity leads to orthopedic & other complications, says Cleveland Clinic’s Steve Niessen. “Every system in the body is affected.”
  • How will obesity market evolve? We don’t know. Lots of resistance (at FDA) to call it a disease. – Brian Dovey, Domain Associates.
  • Dr. [Michael] Roizen’s vision of a good solution to metabolic crises: prevention. Can we intervene earlier and save the whole system money?
  • Michael Roizen, MD, on investing in metabolic disorders: So much unmet need in the U.S. that there will be a lot of winners.
  • J&J’s Brad Vale says metabolic disorders is a great area to invest in, but regulatory hurdles makes the decision tough.
  • Corp. America should remove small impediments, says Citibank’s [Peter] Orszag. Put fruits/veggies at front of cafeteria line; offer onsite gyms.
  • “We’ve never needed innovation in this country more than we do now.” – Former Sen. [Tom] Daschle on challenges facing U.S. healthcare.

Popular Stories

  • Today's news in brief

    BioWorld
    BioWorld briefs for Jan 30, 2025.
  • Today's news in brief

    Briefs
    BioWorld MedTech briefs for Jan. 30, 2026.
  • Brain with stroke illustration

    Brain-derived tau in blood predicts stroke severity and outcome

    BioWorld Science

    Brain-derived tau, a protein that is exclusive to the brain and detectable in the blood, could serve as an indicator of brain damage after an ischemic stroke. The...

  • Centessa’s CNT-9982 shows promise for MDD

    BioWorld Science
    Orexin OX2 receptor agonists have demonstrated the ability to enhance wakefulness in rodent models, as well as in nonhuman primates and patients with narcolepsy...
  • Red and blue bispecific antibodies

    First-in-class ADC targeting DEM-TXX shows high preclinical efficacy

    BioWorld Science
    Researchers at DEM Biopharma Inc. reported preclinical findings demonstrating the efficacy of DEM-301, a bifunctional antibody-drug conjugate (ADC) engineered to...
  • BioWorld
    • Today's news
    • Analysis and data insight
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld MedTech
    • Today's news
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld Asia
    • Today's news
    • Analysis and data insight
    • Australia
    • China
    • Clinical
    • Deals and M&A
    • Financings
    • Newco news
    • Regulatory
    • Science
  • BioWorld Science
    • Today's news
    • Biomarkers
    • Cancer
    • Conferences
    • Endocrine/Metabolic
    • Immune
    • Infection
    • Neurology/Psychiatric
    • NME Digest
    • Patents
  • More
    • About
    • Advertise with BioWorld
    • Archives
    • Article reprints and permissions
    • Contact us
    • Cookie policy
    • Copyright notice
    • Data methodology
    • Infographics: Dynamic digital data analysis
    • Index insights
    • Podcasts
    • Privacy policy
    • Share your news with BioWorld
    • Staff
    • Terms of use
    • Topic alerts
Follow Us

Copyright ©2026. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing